All In MedTech

FDA Clearance Tracker · P010032-S191

Prodigy, Proclaim XR, Proclaim Plus, and Externa Spinal Cord Stimulation (SCS) Systems

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 10, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 10, 2023

Approved

Time to decision

250 days

Received Sep 2, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P010032-S191
Device name
Prodigy, Proclaim XR, Proclaim Plus, and Externa Spinal Cord Stimulation (SCS) Systems
Applicant location
Plano, TX
Received
Sep 2, 2022
Decided
May 10, 2023
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P010032

Device type

Device class
Class III

Every decision under product code LGW

FDA's approval statement

As written in FDA's record.

Approval for expanding the indications to include non-surgical back pain (NSBP) for the tonic and BurstDR stimulation modes, and diabetic peripheral neuropathy (DPN) of the lower extremities for the tonic stimulation mode, for the Prodigy, Proclaim XR, Proclaim Plus, and Externa Spinal Cord Stimulation (SCS) Systems.

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.